Phase1study of a combination of CPT-11 and TS-1 and bevacizumab in patients with metastatic colon cancer - Phase1study of a combination of CPT-11 and TS-1 and bevacizumab in patients with metastatic colon cancer

Department of Surgery, Suita Municipal Hospital0 个研究点目标入组 24 人开始时间: 2008年6月30日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The exclusion criteria were as follows; patients were not eligible for this study if they had a previous serious medical illness or allergy for drugs; had active double cancer; had active infection disease (over 38.0C fever); had perforation of the digestive tract, gastrointestinal paralysis, bowel blockage or history within 1 year before entry; had hypertension which could not control with drug therapy; had serious complication (e.g. interstitial lung disease, lung fibrosis, heart failure, kidney failure, hepatic failure, diabetes mellitus which could not be controlled); had pleural effusion or abdominal dropsy which need therapy; had water solubility diarrhea, in case of the patient who has a colostomy, diarrhea impairs daily life activity; took flucytosine or atazanavir; had brain metastasis; were pregnancy or lactation; could not joint this trial because of mental disorder or psychiatric symptom; were systemically-administered of steroids; were uric protein greater than 2 positive ; were thrombosis; were brain infarction, myocardial infarction or lung infarction before entry; were operated or performed dissected biopsy within 4 weeks before entry; were administered antiplatelet agent for chronic rheumatoid arthritis; were bleeding tendency, coagulation disorder, abnormality of coagulation factor, or administered anticoagulant; except referred to above, physician in charge of this trial gave a diagnosis the patient who can not joint this trail for the safety.

发起方

Department of Surgery, Suita Municipal Hospital